334 related articles for article (PubMed ID: 22284868)
1. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
Martin R
Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on anti-CD25: daclizumab in MS.
Schippling DS; Martin R
Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
[TBL] [Abstract][Full Text] [Related]
3. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
Martin R
Neurodegener Dis; 2008; 5(1):23-6. PubMed ID: 18075271
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab in treatment of multiple sclerosis patients.
Ali EN; Healy BC; Stazzone LA; Brown BA; Weiner HL; Khoury SJ
Mult Scler; 2009 Feb; 15(2):272-4. PubMed ID: 19136546
[TBL] [Abstract][Full Text] [Related]
6. Daclizumab (anti-CD25) in multiple sclerosis.
Pfender N; Martin R
Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
[TBL] [Abstract][Full Text] [Related]
7. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
Immunotherapy; 2010 Jul; 2(4):437. PubMed ID: 20635996
[No Abstract] [Full Text] [Related]
8. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Osherov M; Milo R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
[TBL] [Abstract][Full Text] [Related]
9. In vivo maintenance of human regulatory T cells during CD25 blockade.
Huss DJ; Mehta DS; Sharma A; You X; Riester KA; Sheridan JP; Amaravadi LS; Elkins JS; Fontenot JD
J Immunol; 2015 Jan; 194(1):84-92. PubMed ID: 25416807
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
Sheridan JP; Robinson RR; Rose JW
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792
[TBL] [Abstract][Full Text] [Related]
11. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
Expert Rev Clin Immunol; 2010 Jul; 6(4):509. PubMed ID: 20594121
[No Abstract] [Full Text] [Related]
12. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab and its use in multiple sclerosis treatment.
Milo R; Osherov M
Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab for the treatment of relapsing-remitting multiple sclerosis.
Herwerth M; Hemmer B
Expert Opin Biol Ther; 2017 Jun; 17(6):747-753. PubMed ID: 28286970
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang LN; Zhan S; Xia Y
Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang L; Zhan S; Tan J; Xia Y
Cochrane Database Syst Rev; 2010 Jun; (6):CD008127. PubMed ID: 20556791
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
19. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
Baldassari LE; Rose JW
Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
[TBL] [Abstract][Full Text] [Related]
20. Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
Reardon J; Perumal JS
Drug Des Devel Ther; 2013; 7():1187-93. PubMed ID: 24143075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
